Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Caution on avian flu tests

This article was originally published in The Gray Sheet

Executive Summary

FDA cautions against relying on "rapid" diagnostic tests for influenza avian flu virus (H5N1) in humans in a document posted on the Office of In Vitro Diagnostic Devices Evaluation & Safety website Nov. 14. "None of the FDA-cleared rapid influenza A tests can differentiate influenza A virus subtypes or discriminate between those subtypes that commonly infect humans and those that typically infect birds," the notice says. Quidel announced Oct. 21 that study results for its QuickVue influenza A+B rapid test suggest it can detect H5N1 (1"The Gray Sheet" Nov. 14, 2005, p. 13). Applied BioSystems has a test designed for research and epidemiological use that reportedly can detect the subtype in less than two hours (2"The Gray Sheet" Nov. 14, 2005, p. 14). The World Health Organization has identified 130 confirmed human cases of avian influenza in Asia since 2003...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT022910

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel